Biolegend, 420701, Monensin Solution (1,000X), 1ml

Monensin is a protein transport inhibitor commonly used to enhance intracellular cytokine staining signals by blocking transport processes during cell activation. Especially useful for the intracellular staining of cytokines, monensin leads to the accumulation of most cytokines at the Golgi Complex/Endoplasmic Reticulum (see Jung, et al. , 1993). Optimal conditions for use are cell type and time-dependent. Typically, protein transport inhibitors are included during in vitro cell activation cultures for 4-24 hours prior to harvest (see references below for additional information). Monensin Solution is supplied as a 1,000X solution, which should be diluted to 1X in cell culture medium.
1ml
Formulation: Monensin Solution is supplied as a 1000X working solution in 70% Ethanol. Dilute to 1X in cell culture medium.
Concentration: 2.0 mM
Storage & Handling: Store the solution between 2°C and 8°C. Monensin is known to be toxic; avoid direct body contact. Ethanol is flammable; keep away from sources of fire.
Application: ICFC - Quality tested
Recommended Usage: Dilute the 1000X solution to 1X in the tissue culture medium. It is recommended that cells are cultured with monensin for ≤ 24 hours, as this can become toxic for cell viability.
Application References(PubMed link indicates BioLegend citation): Smeltz RB. 2007. J. Immunol. 178:4786. Fuse S, et al. 2007. J. Immunol. 178:5227. Durkin ET,et al. 2008. Blood 10:1182.PubMed Durkin ET, et al. 2008. Blood 112:5245. PubMed Liu XS, et al. 2009. J. Immunol. 183:51. PubMed Mattarollo SR, et al. 2010. J. Immunol. 184:1242. PubMed Yang M, et al. 2010. J. Immuonl. 184:3321. PubMed Mattarollo SR, et al. 2010. J. Immunol. 184:5663. PubMed Wood MW, et al. 2011. Infect Immun. 79:708. PubMed Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed Fiorenza S, et al. 2012. J. Immunol. 189:5622. PubMed Asgari E, et al. 2013. Blood. 122:3473. PubMed Li D, et al. 2013. Clin Immunol. 149:411. PubMed Bunse CE, et al. 2013. PLoS One. 8:77925. PubMed
Product Citations: Li D, et al. 2013. Clin Immunol. 149:411. PubMed Mattarollo S, et al. 2010. J Immunol. 184:1242. PubMed Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed Duan LJ, et al. 2022. Cell Rep. 40:111284. PubMed Lu C, et al. 2023. Antiviral Res. 212:105556. PubMed Kozlovski S, et al. 2023. Front Immunol. 13:1041552. PubMed Zhou Y, et al. 2023. Front Immunol. 14:1129705. PubMed Changsheng H, et al. 2023. Sci Adv. 9:eade4186. PubMed Comeau K, et al. 2023. Bio Protoc. 13:e4679. PubMed Frankish J, et al. 2023. Front Immunol. 14:1160116. PubMed Patskovsky Y, et al. 2023. Nat Commun. 14:3763. PubMed Pal R, et al. 2020. Curr Protoc Cytom. 92:e69. PubMed Bhatt RS, et al. 2021. Cancer Immunol Res. 9:156. PubMed Yu L, et al. 2022. FEBS J. 289:3241. PubMed Zhang X, et al. 2022. Nat Commun. 13:7582. PubMed Giannou AD, et al. 2023. Immunity. 56:125. PubMed Martinelli M, et al. 2023. iScience. 26:105860. PubMed Zhou H, et al. 2023. Front Immunol. 13:1059687. PubMed Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed Pymm P, et al. 2022. Cell Rep. 38:110449. PubMed Giles JR, et al. 2022. Immunity. 55:557. PubMed Ye L, et al. 2022. Cell Metab. 34:595. PubMed Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed Andrew Mansour, Laurentiu Pop, Ellen Vitetta 2016. PLoS One. 11:e0167618. PubMed Asgari E, et al. 2013. Blood. 122:3473. PubMed Munk R, et al. 2011. PLoS One. 6:e18553. PubMed Pan YG, et al. 2022. Methods Mol Biol. 2574:31. PubMed Aguilar-Pineda JA, et al. 2021. iScience. 24:102993. PubMed Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed Durkin E, et al. 2008. Blood. 112:5245. PubMed Yang M, et al. 2010. J Immunol. 184:3321. PubMed Cook CP, et al. 2022. Cell Rep Med. 3:100715. PubMed Tian M, et al. 2022. J Clin Invest. 132:. PubMed Kimura I, et al. 2022. Cell Rep. 38:110218. PubMed Gao F, et al. 2021. Front Cell Infect Microbiol. 10:593805. PubMed Izumi K, et al. 2021. Immunohorizons. 5:687. PubMed Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed Martens A, et al. 2020. Nat Immunol. 21:381. PubMed Theeb W, et al. 2017. Infect Immun . 10.1128/IAI.00475-16. PubMed Al-Attar A, et al. 2016. Data Brief. 8: 536-44. PubMed Joosten S, et al. 2016. PLoS Pathog. 12: 1005687. PubMed Fiorenza S, et al. 2012. J Immunol. 189:5622. PubMed Rana A, et al. 2020. Front Immunol. 11:536. PubMed Datta A, et al. 2022. J Fungi (Basel). 8:. PubMed Douthwaite J, et al. 2017. J Immunol. 198(1):528-537. PubMed Meyer C, Key P 2017. Imm Inflam Dis. 10.1002/iid3.156. PubMed Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed Geisness AC, et al. 2021. Haematologica. Online ahead of print. PubMed Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed Ries M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006506. PubMed Steinbuck MP, et al. 2021. Sci Adv. 7: . PubMed Acharya A, et al. 2020. J Virol. 95:e01657. PubMed Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed Shenoy AT, et al. 2021. Nat Commun. 12:5834. PubMed Imani J, et al. 2021. JCI Insight. 6:. PubMed Elliott PR, et al. 2021. Cell Rep. 37:109777. PubMed Bunting MD, et al. 2022. Sci Adv. 8:eabk3327. PubMed Uddin MN, et al. 2022. Brain Behav Immun Health. 26:100563. PubMed Mittal P, et al. 2020. Cancers (Basel). :12. PubMed Gross C, et al. 2016. Neurol Neuroimmunol Neuroinflamm. 3: e289. PubMed Orlov M, et al. 2017. PLoS One.. 10.1371/journal.pone.018296. PubMed Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed Vacaflores A, et al. 2016. PLoS One. 11: 0157175. PubMed Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed Huang RS, et al. 2021. Curr Protoc. 1:e246. PubMed Nice T, et al. 2016. PLoS One. 12: 1005684. PubMed Krishnan A, et al. 2020. Am J Pathol. 190:1284. PubMed Ngwenyama N, et al. 2019. JCI Insight. 4:e125527. PubMed Chen YF, et al. 2019. J Biomed Sci. 26:85. PubMed Loeuillard E, et al. 2020. J Clin Invest. 130:5380. PubMed Liu X, et al. 2009. J Immunol. 183:51:00. PubMed Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed de Picciotto S, et al. 2022. Nat Commun. 13:3866. PubMed Shafer S, et al. 2021. J Allergy Clin Immunol. 148:256. PubMed Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed Ren Y, et al. 2015. Biochim Biophys Acta. Available online 14 August 2015. PubMed Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed Wood M, et al. 2011. Infect Immun. 79:708. PubMed Dimeloe S, et al. 2016. J Immunol. 196: 106 - 114. PubMed Bunse C, et al. 2013. PLoS One. 8:77925. PubMed Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed Landi A, et al. 2017. Vaccine.. 10.1016/j.vaccine.2017.10.072. PubMed Liu X, et al. 2020. Ther Adv Med Oncol. 12:1758835920910347. PubMed Burger ML, et al. 2021. Cell. 184:4996. PubMed Bonavita E, et al. 2020. Immunity. 1215:53. PubMed Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed Seenappa LM, et al. 2022. NPJ Vaccines. 7:128. PubMed Krishna B, et al. 2016. Sci Rep. 6: 24674. PubMed Schridde A, et al. 2017. Mucosal Immunol. 10.1038/mi.2016.142. PubMed Ruland C, et al. 2017. Brain Behav Immun. 10.1016/j.bbi.2017.06.010. PubMed Mattarollo S, et al. 2010. J Immunol. 184:5663. PubMed Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed Laczkó D, et al. 2020. Immunity. 53:724. PubMed Marvin S, et al. 2017. J Virol. 10.1128/JVI.01417-16. PubMed Kumar S, et al. 2021. JCI Insight. 6:e145228. PubMed Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed
Antigen References: 1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 Detection of Intracellular Cytokines by Flow Cytometry (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD). 2. Sander B, et al. 1991. Immunol. Rev. 119:65. 3. Sander B, et al. 1993. J. Immunol. Meth. 166:201. 4. Prussin C, et al. 1995. J. Immunol. Meth. 188:117. 5. Jung T, et al. 1993. J. Immunol. Meth. 159:197.
Gene ID: NA
Regulatory Status: RUO
Q: How do I choose monensin or Brefeldin A solution?
A: Generally, Brefeldin A is more toxic for longer term incubations, so for shorter stimulations (6 hrs or less) use Brefeldin A.  For longer stimulations use monensin.  We recommend optimization for each cell type and protocol.